Memory T cells promote allograft rejection particularly in co-stimulation blockade-based immunosuppressive regimens. Here we show that the CD2-specific fusion protein alefacept (lymphocyte function-associated antigen-3-Ig; LFA -3-Ig) selectively eliminates memory T cells and, when combined with a co-stimulation blockade-based regimen using cytotoxic T lymphocyte antigen-4 (CTLA-4)-Ig, a CD80-and CD86-specific fusion protein, prevents renal allograft rejection and alloantibody formation in nonhuman primates. These results support the immediate translation of a regimen for the prevention of allograft rejection without the use of calcineurin inhibitors, steroids or pan-T cell depletion.
Memory T cells promote allograft rejection particularly in co-stimulation blockade-based immunosuppressive regimens. Here we show that the CD2-specific fusion protein alefacept (lymphocyte function-associated antigen-3-Ig; LFA -3-Ig) selectively eliminates memory T cells and, when combined with a co-stimulation blockade-based regimen using cytotoxic T lymphocyte antigen-4 (CTLA-4)-Ig, a CD80-and CD86-specific fusion protein, prevents renal allograft rejection and alloantibody formation in nonhuman primates. These results support the immediate translation of a regimen for the prevention of allograft rejection without the use of calcineurin inhibitors, steroids or pan-T cell depletion.
Calcineurin inhibitors and glucocorticosteroids are commonly used to prevent the rejection of allografted organs; however, both agents promote many side effects 1 . Blockade of the CD28 co-stimulation pathway through inhibition of its ligands, CD80 and CD86 (B7 molecules), has been suggested as a means of preventing allograft rejection without these side effects, and, indeed, the B7-specific fusion protein CTLA4-Ig has been shown to induce permanent engraftment of allografts in some rodent models, particularly when combined with the drug sirolimus, donor-specific transfusion (DST) or both 2, 3 . Unfortunately, CTLA-4-Ig with or without sirolimus is insufficient to prevent rejection in primates 4 .
Several mechanisms of co-stimulation blockade-resistant rejection have been demonstrated experimentally, many of them implicating T cells with a memory phenotype 5 . T cells gain this phenotype through previous antigen exposure, heterologous crossreactivity between alloantigens and environmental pathogens, or homeostatic expansion and thereafter either lack CD28 or otherwise have reduced co-stimulation requirements 6, 7 . We have therefore been interested in developing adjuvant therapies that transiently but specifically neutralize memory T (T M ) cells to facilitate the clinical use of co-stimulation blockade in transplantation, preferably adopting maneuvers that avoid T M cell development through homeostatic activation (for example, pan-T cell depletion).
One candidate agent is LFA-3-Ig (also called alefacept), a dimeric fusion protein consisting of the CD2-binding portion of the human lymphocyte function-associated antigen-3 (LFA-3) linked to the Fc portion of human IgG1. LFA-3-Ig is thought to neutralize the effect of CD2-expressing cells through several mechanisms including complement-mediated lysis and interruption of CD2's interactions with LFA-3, limiting helper T cell adhesion to antigen-presenting cells and disrupting the engagement of effector T cell receptor engagement with antigen and major histocompatibility complex molecules. It is currently approved for the clinical treatment of psoriasis, and its therapeutic effect has been linked to its ability to deplete T M cells [8] [9] [10] . We therefore investigated LFA-3-Ig as an adjuvant agent for use with the co-stimulation blockade-based regimen of CTLA-4-Ig, sirolimus and/or DST.
We treated renal allografted rhesus macaques with LFA-3-Ig, CTLA-4-Ig or both weekly for 8 weeks, oral sirolimus daily for 90 d and pretransplant whole blood DST (see Supplementary Methods and Supplementary Fig. 1 ). Control macaques receiving no treatment, sirolimus alone, sirolimus with DST, sirolimus with DST and CTLA-4-Ig, or sirolimus with DST and LFA-3-Ig had progressively increased survival; however, no macaques remained rejection-free beyond their treatment period (Fig. 1a and Supplementary Table 1) , and all macaques developed alloantibody by the onset of rejection (Supplementary Fig. 2) . In comparison, when we combined both LFA-3-Ig and CTLA-4-Ig with sirolimus with or without DST, we observed significantly prolonged survival compared to all other treatment groups (Fig. 1a) . The groups did not differ by sirolimus level or donor-directed mixed lymphocyte reactivity (Supplementary Table 1 ). These macaques remained alloantibody-free while receiving both LFA-3-Ig and CTLA-4-Ig ( Supplementary Fig. 2 ), and five of eight macaques receiving the combination therapy remained rejectionfree beyond the period of treatment (490 d) (Fig. 1a) . Thus, LFA-3-Ig was clearly additive and potentially synergistic (given that survival seems to exceed that expected for additive effects) with this costimulation blockade-based regimen.
We used polychromatic flow cytometry (PFC) to evaluate the effect of LFA-3-Ig treatment on naive and T M cell subsets 11 (Fig. 1b , Supplementary Methods and Supplementary Fig. 3 ). Although there was no gross lymphopenia, there was a general trend toward decreased absolute T cell numbers in LFA-3-Ig-treated macaques, with a greater reduction in CD8 + cells and an increase in the CD4 + to CD8 + ratio that reversed after the withdrawal of LFA-3-Ig compared to macaques not receiving LFA-3-Ig (data not shown). This modest decrease in lymphocyte counts was attributable to a selective depletion in T M cells without alteration of the numbers of naive T cells. In particular, we observed the most substantial depletion within the T effector memory (T EM ; CD28 -CD95 + ) subset of CD4 + and CD8 + T cells (Fig. 1c) . T EM counts were markedly (P ¼ 0.007, two-tailed Student's t test comparing before and after transplant cell counts) decreased after 3 weeks of LFA-3-Ig therapy. At the time of rejection or killing, T EM counts in LFA-3-Ig-treated macaques had returned to normal (Fig. 1c) , suggesting that more prolonged treatment might improve survival. We did not observe this decrease in T EM cells in macaques not treated with LFA-3-Ig (Fig. 1c) . Notably, evaluation of CD2 and CD3 expression in peripheral blood T cells from naive macaques indicated that their CD28 + T cells were overwhelmingly CD2 lo CD3 hi , whereas their CD28 -T-cells were conversely CD2 hi CD3 lo , providing an explanation for the T EM selective effects of LFA-3-Ig (Fig. 1d,e) . Notably, there was an inverse relationship between the surface expression of CD2 (the target of LFA-3-Ig) and CD28 (the relevant receptor whose ligand binding is blocked by CTLA-4-Ig).
All macaques at one month after transplant showed modest lymphocytic infiltrates in surveillance biopsies studied by multicolor immunohistochemistry (Fig. 1f and Supplementary Methods). Of note, whereas T cell infiltrates were present in all macaques, those macaques that did not receive LFA-3-Ig tended to show a more heterogeneous infiltrate, including monocytes in addition to T cells (Fig. 1f) . All macaques reaching the endpoint criteria of depressed 
t r a n s p la n t A f t e r t r a n s p la renal function (see Supplementary Methods) showed allograft rejection upon histological analysis after necropsy (data not shown). However, we killed two macaques with normally functioning, rejection-free allografts at days 168 and 243 after they developed alloantibody for histological assessment. These macaques' allografts contained focal perivascular aggregates of T and B cells with minimal or no monocytes ( Fig. 1f and Supplementary Fig. 4 ) and without tubulitis or vasculitis. Despite normal renal allograft function and no clinical signs of rejection, we observed multiple focal and highly organized cellular infiltrates. The paucity of monocytes in these infiltrates is consistent with previously reported results of allografts maintaining normal function under co-stimulation blockade-based therapies, in that pure T cell aggregates behaved in a benign fashion, whereas those allografts that contained monocytes were associated with functional impairment 12 . In comparison, examination of rejecting macaques by an identical IHC staining regimen showed diffuse infiltrates without focal organization and showing greater cellular heterogeneity (data not shown). Notably, there were higher numbers of macrophages observed per objective field in biopsies from rejecting kidneys compared to the infiltrates seen in nonrejecting allografts (data not shown), which has been shown to be of functional importance 13 .
To investigate the effect of LFA-3-Ig on alloreactive T M cells, we used mixed lymphocyte cultures (MLCs) to specifically evaluate the relationship between the alloresponsiveness of CD4 + and CD8 + T cells and their surface expression of CD2. We labeled responder lymphocytes with carboxyfluorescein succinimidyl ester (CFSE) to enable the identification of responding cells by generation of cell division ( Fig. 2a and Supplementary Methods) , and we individually examined each division for maturation phenotype and CD2 expression. Responding cells progressively increased CD2 expression, leaving highly alloresponsive cells markedly decorated with the LFA-3-Ig target compared to nonresponding cells (Fig. 2b) . Similarly, cells that differentiated into cytokine-producing cells (those producing interferon-g (IFN-g) ), tumor necrosis factor-a (TNF-a) and/or interleukin-2 (IL-2)) in response to alloantigen stimulation progressively gained CD2 expression commensurate with their acquisition of cytokine secretion capabilities, with the highest CD2 expression in those cells with polyfunctionality (Fig. 2c) , cells previously shown to be more robust and terminally differentiated effectors 14 . In keeping with this target pattern, CTLA-4-Ig and LFA-3-Ig each mediated a dose-dependent inhibition of proliferation for both CD4 + and CD8 + T cells when the fusion proteins were added to MLCs, and the combination induced an additive reduction in the percentage of cells divided across the three logs of concentration (Fig. 2d,e) .
These results show that a combination of LFA-3-Ig, CTLA-4-Ig and sirolimus markedly prolongs renal allograft survival and delays the onset of alloantibody formation in nonhuman primates and that the effect lasts beyond the period of therapy in most macaques. All components of the regimen seem to be involved in its efficacy, as individual agents were ineffective in preventing rejection or antibody formation. The mechanism underlying the salutary effect of LFA-3-Ig seems to be related to increasing CD2 density on alloresponsive cells, particularly CD28 -T EM cells, which are least susceptible to co-stimulation blockade and most alloresponsive. These data are consistent with a model in which the transient elimination of co-stimulation blockaderesistant T M cells fosters an environment that more closely resembles that seen in naive murine models. They support the development of a clinically applicable regimen for the prevention of allograft rejection in humans without the use of those therapeutic modalities responsible for the majority of immunosuppressive side effects.
